 |
| "Medtronic Inc.’s CoreValve is photographed at an American College of Cardiology Conference in Washington, on Saturday. A new study gives a big boost to fixing a bad aortic valve, the heart's main gate, without open-heart surgery." |
The
results were reported Saturday at an American College of Cardiology
conference in Washington and prompted some doctors to predict that in
the near future, far fewer people will be having the traditional
operation.
'It's going to be very
hard to tell a patient that if they need an aortic valve, surgery is
going to be their best option,' said one of the conference leaders, Dr.
Prediman K. Shah of Cedars Sinai Heart Institute in Los Angeles.
Several
hundred thousand Americans have a bad aortic valve, which can stiffen
and narrow with age, keeping blood from passing through as it should.
Until a few years ago, the only solution was a major operation to open
the chest, cut out the bad valve and sew in a new one.
Earlier this year, (...)
Medtronic Inc.'s CoreValve was approved for treating people at too
high risk to have surgery. The new study tested it in nearly 800 people
less sick — eligible for the operation but still with elevated risks.
One year after treatment, 19 percent of the surgery patients but only 14 percent of those given a CoreValve had died.
'It's
a great leap forward' for fixing valves through blood vessels, said Dr.
David Kandzari of Piedmont Heart Institute in Atlanta.
The
study was paid for by Medtronic, and many study leaders consult for
Medtronic, Edwards or other heart device makers. Results also were
published online by the New England Journal of Medicine."
Articles
